Patients taking Italfarmaco’s drug also saw a slower decline in physical function over 18 ... which is widely used in DMD therapy assessments. The drug was well-tolerated, with the most common ...

The company has previously said that it sees deramiocel as an add-on therapy to current chronic treatments for DMD, including corticosteroids and exon-skipping therapies. Deramiocel is approaching ...

England’s National Institute for Health and Care Excellence (NICE) has recommended Santhera Pharmaceuticals’ treatment for Duchenne muscular dystrophy (DMD) Agamree (vamorolone) following a ...

Shares of Sarepta SRPT rose nearly 34% in after-market trading on Thursday after it announced that the FDA approved the expanded use of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys.

The company's primary focus is on its lead candidate, SGT-003, a novel gene therapy designed to address the underlying cause of DMD. Despite the promise of its research, Solid Biosciences ...

China’s National Medical Products Administration (NMPA) has approved Santhera Pharmaceuticals’ AGAMREE (vamorolone), used to treat Duchenne muscular dystrophy (DMD) in patients aged four years ...

This submission could potentially lead to the first approved therapy for this aspect of DMD if the FDA grants approval. According to InvestingPro data, the company's stock has surged nearly 192% ...

SAN DIEGO - Capricor Therapeutics (NASDAQ: NASDAQ:CAPR), a biotechnology company with a market capitalization of $627 million, has announced the completion of its Biologics License Application (BLA) ...

4 DMD is a rare genetic disorder that causes ... While there is no cure, treatments like physical therapy, medications, and emerging therapies aim to slow progression and improve quality of ...